PRTN3 and systemic lupus erythematosus: These observations were replicated in an analysis of two well-defined European cohorts of patients with SLE that showed similar American College of Rheumatology-defined phenotypes in those with and without ACPA [25], while the study by Ziegelasch reported ACPA positive rates as 5.4–6.8%.